ATE423129T1 - Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs - Google Patents
Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebsInfo
- Publication number
- ATE423129T1 ATE423129T1 AT01990038T AT01990038T ATE423129T1 AT E423129 T1 ATE423129 T1 AT E423129T1 AT 01990038 T AT01990038 T AT 01990038T AT 01990038 T AT01990038 T AT 01990038T AT E423129 T1 ATE423129 T1 AT E423129T1
- Authority
- AT
- Austria
- Prior art keywords
- lyn
- inhibitors
- treatment
- prostate cancer
- signal transduction
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000019491 signal transduction Effects 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/735,279 US20020019346A1 (en) | 1997-05-21 | 2000-12-11 | Treatment of prostate cancer by inhibiting lyn tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE423129T1 true ATE423129T1 (de) | 2009-03-15 |
Family
ID=24955113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01990038T ATE423129T1 (de) | 2000-12-11 | 2001-12-11 | Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20020019346A1 (de) |
| EP (1) | EP1366063B1 (de) |
| AT (1) | ATE423129T1 (de) |
| AU (1) | AU2002228913A1 (de) |
| DE (1) | DE60137721D1 (de) |
| WO (1) | WO2002047710A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003015820A1 (en) * | 2001-08-10 | 2003-02-27 | Takeda Chemical Industries, Ltd. | GnRH AGONIST COMBINATION DRUGS |
| EP1509545B8 (de) * | 2002-05-31 | 2010-10-13 | Merck Serono Biodevelopment SAS | Homotrimerer, erweiterter globulärer kopf von obg3 und verwendungen davon |
| US20070010468A1 (en) * | 2003-04-23 | 2007-01-11 | Georgetown University | Methods and compositions for the inhibition of stat5 in prostate cancer cells |
| KR101452518B1 (ko) * | 2005-08-22 | 2014-10-21 | 멜리어 파마슈티칼스 아이, 인코포레이티드 | Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제 |
| EP2120581A4 (de) * | 2007-02-20 | 2011-03-16 | Melior Pharmaceuticals I Inc | Verfahren zur identifikation von aktivatoren der lyn-linase |
| EP2180894A4 (de) * | 2007-07-23 | 2012-08-29 | Melior Pharmaceuticals I Inc | Verfahren zur aktivierung von irs-1 und akt |
| US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
| WO2011150300A1 (en) | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
| EP3609500B1 (de) | 2017-04-10 | 2024-11-13 | Melior Pharmaceuticals I, Inc. | Behandlung von adipozyten |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2131389A1 (en) * | 1992-03-02 | 1993-09-16 | John M. Maraganore | Thrombin receptor antagonists |
| US5508383A (en) * | 1994-03-09 | 1996-04-16 | Tap Holdings Inc. | Cyclic peptide LHRH antagonists |
| US6723694B1 (en) * | 1997-05-21 | 2004-04-20 | The Children's Medical Center Corp. | Short peptides which selectively modulate intracellular signalling |
| DE69940808D1 (de) * | 1998-03-04 | 2009-06-10 | Bristol Myers Squibb Co | Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren |
-
2000
- 2000-12-11 US US09/735,279 patent/US20020019346A1/en not_active Abandoned
-
2001
- 2001-12-11 US US10/012,030 patent/US20020151497A1/en not_active Abandoned
- 2001-12-11 EP EP01990038A patent/EP1366063B1/de not_active Expired - Lifetime
- 2001-12-11 AT AT01990038T patent/ATE423129T1/de not_active IP Right Cessation
- 2001-12-11 DE DE60137721T patent/DE60137721D1/de not_active Expired - Fee Related
- 2001-12-11 WO PCT/US2001/047444 patent/WO2002047710A2/en not_active Ceased
- 2001-12-11 AU AU2002228913A patent/AU2002228913A1/en not_active Abandoned
-
2006
- 2006-12-21 US US11/614,157 patent/US20080045460A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60137721D1 (de) | 2009-04-02 |
| EP1366063A2 (de) | 2003-12-03 |
| EP1366063B1 (de) | 2009-02-18 |
| WO2002047710A2 (en) | 2002-06-20 |
| US20020019346A1 (en) | 2002-02-14 |
| US20080045460A1 (en) | 2008-02-21 |
| US20020151497A1 (en) | 2002-10-17 |
| AU2002228913A1 (en) | 2002-06-24 |
| WO2002047710A3 (en) | 2003-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004024909D1 (de) | Platinkomplexe zur behandlung von tumoren | |
| NO995544D0 (no) | Forbindelser og metoder for inhibering av ekspresjonen av VCAM-1 | |
| ATE269295T1 (de) | Btk inhibitoren und verfahren zur identifizierung und verwendung | |
| DE69815090D1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| DE60135029D1 (de) | Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis | |
| DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
| ATE316785T1 (de) | Jak-3 hemmer zur behandlung von allergischen störungen | |
| ATE295735T1 (de) | Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs | |
| ATE527022T1 (de) | Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie | |
| ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
| DE69722621D1 (de) | Inhibierung von dns reparatur zur erhöhung der sensitivität für p53-vermittelte suppression | |
| ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
| DE60137721D1 (de) | Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs | |
| EP1490385A4 (de) | Jagged-2-inhibitoren zur induktion von apoptose | |
| ATE333869T1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
| DE60123138D1 (de) | Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| ATE410235T1 (de) | Behandlung von ballastwasser | |
| DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
| ATE267194T1 (de) | Medikamente geeignet zur behandlung von proliferativen erkrankungen | |
| ATE332970T1 (de) | Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums | |
| DE60327793D1 (de) | Modulation der s6-kinaseaktivität zur behandlung von adipositas | |
| DE60312988D1 (de) | Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea | |
| DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| DE69924385D1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |